Floatz logo

Quemliclustat

Metastatic Bladder Giant Cell Urothelial Carcinoma

Fred Hutchinson Cancer CenterSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Metastatic Bladder Giant Cell Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 2/3B
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 2/3B
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2/3B
CIS-DIAMMINEDICHLOROPLATINUM II
Vasgene Therapeutics, Inc
Phase 2/3B
Relatlimab
National Cancer Institute (NCI)
Phase 2/3B

View all 15 →

Same molecule, other indications

Quemliclustat is also rated in:

pancreatic ductal adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
metastatic prostate carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →